Non-squamous non-small-cell lung cancer (NSQ NSCLC)

Clinical trials for Non-squamous non-small-cell lung cancer (NSQ NSCLC) explained in plain language.

Never miss a new study

Get alerted when new Non-squamous non-small-cell lung cancer (NSQ NSCLC) trials appear

Sign up with your email to follow new studies for Non-squamous non-small-cell lung cancer (NSQ NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Lung cancer drug combo trial halted early

Disease control Stopped early

This study tested a new drug (tusamitamab ravtansine) combined with pembrolizumab and chemotherapy in 57 people with advanced non-squamous non-small-cell lung cancer that has a specific marker (CEACAM5). The goal was to see if the combination was safe and shrank tumors. The trial…

Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC)

Phase 2 • Sponsor: Sanofi • Aim: Disease control

Last updated Jun 27, 2026 07:55 UTC

Non-squamous non-small-cell lung cancer (NSQ NSCLC)

Get alerted when new Non-squamous non-small-cell lung cancer (NSQ NSCLC) trials appear

Lung cancer drug combo trial halted early